

Correction: What role for ▼colesevelam?

Our article *What role for ▼colesevelam?* (DTB 2009; 47: 53–5) incorrectly quoted the National Institute for Health and Clinical Excellence guideline on lipid modification¹ in stating that for secondary prevention of cardiovascular disease, it recommended “simvastatin 40mg daily, potentially increasing to this to simvastatin 80mg daily or a drug of similar efficacy or acquisition cost.” In reality, the latter part of this quote should have read “similar efficacy and acquisition cost”. This error does not affect the article’s *Conclusion*.

1. National Collaborating Centre for Primary Care, 2008. *Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease* [online]. London: Royal College of General Practitioners. Available: <http://www.nice.org.uk/nicemedia/pdf/CG67FullGuideline1.pdf> [Accessed 21 May 2009].